Correspondence 0001193125-25-067201 from NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS
Date: March 28, 2025 · CIK: 0000906709 · Accession: 0001193125-25-067201
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286222
Letter
Re: Nektar Therapeutics
VIA EDGAR March 28, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill
Acceleration Request for Registration Statement on Form S-3
File No. 333-286222 Dear Laura Hamill, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Nektar Therapeutics (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to April 1, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Justin Platt at (212) 459-7340. If you have any questions regarding this request, please contact Sam Zucker of Goodwin Procter LLP at (650) 752-3232 or Justin Platt at (212) 459-7340.
Sincerely,
NEKTAR THERAPEUTICS
/s/ Howard W. Robin
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR March 28, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Nektar Therapeutics Acceleration Request for Registration Statement on Form S-3 File No. 333-286222 Dear Laura Hamill, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Nektar Therapeutics (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to April 1, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Justin Platt at (212) 459-7340. If you have any questions regarding this request, please contact Sam Zucker of Goodwin Procter LLP at (650) 752-3232 or Justin Platt at (212) 459-7340. Sincerely, NEKTAR THERAPEUTICS /s/ Howard W. Robin Howard W. Robin President and Chief Executive Officer cc: Howard W. Robin, Nektar Therapeutics Sam Zucker, Goodwin Procter LLP Justin Platt, Goodwin Procter LLP